ADZENYS ER CII
Generic Name and Formulations:
Amphetamine ext-rel 1.25mg/mL; oral susp; orange-flavored.
Indications for ADZENYS ER:
Attention deficit hyperactivity disorder.
Adults and Children:
Do not substitute for other amphetamine products on a mg-per-mg basis. <6yrs: not established. Individualize. Take in the AM. 6–17yrs: initially 6.3mg (5mL) once daily; increase in increments of 3.1mg (2.5mL) or 6.3mg (5mL) at weekly intervals; max 18.8mg (15mL) daily (if 6–12yrs) or 12.5mg (10mL) daily (if 13–17yrs). >17yrs: 12.5mg (10mL) once daily. Switching from other amphetamine products: see full labeling.
During or within 14 days of MAOIs.
Abuse and dependence.
Abuse potential (monitor). Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for serotonin syndrome; discontinue if occurs. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor BP, HR, growth in children. Reevaluate periodically. Labor & delivery. Pregnancy; monitor for neonatal withdrawal symptoms. Nursing mothers: not recommended.
See Contraindications. Hypertensive crisis with MAOIs (including linezolid, IV methylene blue). Increased risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort), CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine, ritonavir); consider alternatives; if needed, initiate with lower doses and monitor. Potentiated by urinary alkalinizers (eg, sodium bicarbonate, acetazolamide, some thiazides); avoid. Antagonized by acidifiers (eg, ascorbic acid, guanethidine, reserpine, glutamic acid HCl): increase dose as needed. Concomitant gastric pH modulators (eg, omeprazole, esomeprazole, pantoprazole, cimetidine): not recommended. May potentiate TCAs or sympathomimetics; adjust dose or use alternatives. May interfere with urinary steroid tests.
Loss of appetite, insomnia, abdominal pain, emotional lability, vomiting, nervousness, nausea, fever; hypertension. Also adults: dry mouth, headache, weight loss, anxiety, agitation, dizziness, tachycardia, diarrhea, asthenia, urinary tract infections.
To register pregnant patients in the National Pregnancy Registry for Psychostimulants, call (866) 961-2388.
Renal and Urology News Articles
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)